129 related articles for article (PubMed ID: 35713434)
1. KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry.
Gong Y; Zhou L; Ding L; Zhao J; Wang Z; Ren G; Zhang J; Mao Z; Zhou R
Medicine (Baltimore); 2022 Jun; 101(24):e29312. PubMed ID: 35713434
[TBL] [Abstract][Full Text] [Related]
2. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
3. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma.
Zhu QY
Sci Rep; 2023 Apr; 13(1):6310. PubMed ID: 37072474
[TBL] [Abstract][Full Text] [Related]
5. [Screening of Differential Expression Autophagy Genes Related to the Prognosis of Diffuse Large B-Cell Lymphoma and Establishment of an Autophagy Model].
Zhang JD; Zhang HM; Lu D; Wang ZN; Chen HR; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1101-1108. PubMed ID: 35981368
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
Luo B; Gu YY; Wang XD; Chen G; Peng ZG
Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
[TBL] [Abstract][Full Text] [Related]
8. An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.
Zhou F; Chen L; Lu P; Cao Y; Deng C; Liu G
BMC Cancer; 2023 Jul; 23(1):641. PubMed ID: 37430195
[TBL] [Abstract][Full Text] [Related]
9.
Cheng C; Wu X; Shen Y; Li Q
Cancer Manag Res; 2020; 12():13241-13257. PubMed ID: 33380832
[TBL] [Abstract][Full Text] [Related]
10. Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma.
Charwudzi A; Meng Y; Hu L; Ding C; Pu L; Li Q; Xu M; Zhai Z; Xiong S
PeerJ; 2021; 9():e12394. PubMed ID: 34760386
[TBL] [Abstract][Full Text] [Related]
11. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma.
Sun C; Cheng X; Wang C; Wang X; Xia B; Zhang Y
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30393234
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of hub genes and key pathway in two subtypes of diffuse large B-cell lymphoma by bioinformatics and basic experiments.
Li Q; Meng Y; Hu L; Charwudzi A; Zhu W; Zhai Z
J Clin Lab Anal; 2021 Nov; 35(11):e23978. PubMed ID: 34545634
[TBL] [Abstract][Full Text] [Related]
14. Analysis of endoplasmic reticulum stress-related gene signature for the prognosis and pattern in diffuse large B cell lymphoma.
Zhang C; Lin Q; Li C; Chen Z; Deng M; Weng H; Zhu X
Sci Rep; 2023 Aug; 13(1):13894. PubMed ID: 37626099
[TBL] [Abstract][Full Text] [Related]
15. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
17. Methylation silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma.
Cao B; Guo X; Huang L; Wang B; Wang W; Han D; Zhang W; Zhong K
Aging (Albany NY); 2021 Jul; 13(13):17768-17788. PubMed ID: 34252883
[TBL] [Abstract][Full Text] [Related]
18. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
19. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
20. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
